IKZF1 and precursor B-cell acute lymphoblastic leukemia: Notably, a recent study has recently refined the prognostic value of IKZF1 alterations in a large cohort of paediatric B-ALL, demonstrating that MRD-positivity in patients with IKZF1plus signature (i.e., IKZF1 deletion plus other co-occurring deletions such as CDKN2A, PAX5 or PAR1) are associated with a very-poor prognosis [107].